DETAILS, FICTION AND ABBV-744 IN ACUTE MYELOID LEUKEMIA (AML)

In Phase A, individuals will receive different doses and schedules of oral ABBV-744 tablet to recognize safe dosing program. Added contributors are going to be enrolled for the recognized monotherapy dosign regimen. In Section B, participants will get oral ruxolitinib and ABBV-744 will likely be offered as "add-on" therapy. In Phase C, members will